• 1
    Strom SC, Fisher RA, Thompson MT, Sanyal AJ, Cole PE, Ham JM, Posner MP. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63:559569.
  • 2
    Muraca M, Gerunda G, Neri D, Vilei MT, Granato A, Feltracco P, Meroni M, et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359:317318.
  • 3
    Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin PI, Dorko K, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338:14221426.
  • 4
    Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR Jr, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254:18021805.
  • 5
    Guha C, Roy-Chowdhury N, Jauregui H, Roy-Chowdhury J. Hepatocyte-based gene therapy. J Hepatobiliary Pancreat Surg 2001; 8:5157.
  • 6
    Wilson JM. Adenovirus-mediated gene transfer to liver. Adv Drug Deliv Rev 2001; 46:205209.
  • 7
    Gupta S, Wilson JM, Chowdhury JR. Hepatocyte transplantation: development of new systems for liver repopulation and gene therapy. Semin Liver Dis 1992; 12:321331.
  • 8
    Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ 3rd, Stein EA, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:11481154.
  • 9
    Poznansky M, Lever A, Bergeron L, Haseltine W, Sodroski J. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol 1991; 65:532536.
  • 10
    Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272:263267.
  • 11
    Pan D, Gunther R, Duan W, Wendell S, Kaemmerer W, Kafri T, Verma IM, et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 2002; 6:1929.
  • 12
    Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17:314317.
  • 13
    Park F, Ohashi K, Chiu W, Naldini L, Kay MA. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 2000; 24:4952.
  • 14
    Pfeifer A, Kessler T, Yang M, Baranov E, Kootstra N, Cheresh DA, Hoffman RM, et al. Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol Ther 2001; 3:319322.
  • 15
    VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, Berneman Z, Collen D, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100:813822.
  • 16
    McIntyre M, Desdouets C, Senamaud-Beaufort C, Laurent-Winter C, Lamas E, Brechot C. Differential expression of the cyclin-dependent kinase inhibitor P27 in primary hepatocytes in early-mid G1 and G1/S transitions. Oncogene 1999; 18:45774585.
  • 17
    Mazier D, Beaudoin RL, Mellouk S, Druilhe P, Texier B, Trosper J, Miltgen F, et al. Complete development of hepatic stages of Plasmodium falciparum in vitro. Science 1985; 227:440442.
  • 18
    Sirven A, Ravet E, Charneau P, Zennou V, Coulombel L, Guetard D, Pflumio F, et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 2001; 3:438448.
  • 19
    Sirven A, Pflumio F, Zennou V, Titeux M, Vainchenker W, Coulombel L, Dubart-Kupperschmitt A, et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000; 96:41034110.
  • 20
    Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7:927933.
  • 21
    Kay MA, Baley P, Rothenberg S, Leland F, Fleming L, Ponder KP, Liu T, et al. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci U S A 1992; 89:8993.
  • 22
    Andreoletti M, Loux N, Vons C, Nguyen TH, Lorand I, Mahieu D, Simon L, et al. Engraftment of autologous retrovirally transduced hepatocytes after intraportal transplantation into nonhuman primates: implication for ex vivo gene therapy. Hum Gene Ther 2001; 12:169179.
  • 23
    Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96:11731176.
  • 24
    Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol 2002; 261:245254.
  • 25
    Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101:173185.
  • 26
    Zennou V, Serguera C, Sarkis C, Colin P, Perret E, Mallet J, Charneau P. The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol 2001; 19:446450.
  • 27
    Nguyen T, Oberholzer J, Birraux J, Majno P, Morel P, Trono D. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther 2002; 6:199.
  • 28
    Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, Rogiers X, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33:981988.
  • 29
    Strom SC, Fisher RA, Rubinstein WS, Barranger JA, Towbin RB, Charron M, Mieles L, et al. Transplantation of human hepatocytes. Transplant Proc 1997; 29:21032106.
  • 30
    Chen YT, Amalfitano A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 2000; 6:245251.
  • 31
    Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N, Plotz P, Chen YT. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A 1999; 96:88618866.
  • 32
    Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther 1999; 10:16671682.
  • 33
    Guidotti JE, Mignon A, Haase G, Caillaud C, McDonell N, Kahn A, Poenaru L. Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice. Hum Mol Genet 1999; 8:831838.